Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H5N8 Influenza Vaccine with Matrix-M in Healthy Adults
NCT07779408Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Aug 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza (4 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate Adverse Events at 30 minutes, Number of participants experiencing solicited administration site reactions at 8 days and 11 more. Started Aug 2026; status: recruiting.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT07779408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779408.